• Presenting Phase 2b development of MH002 for ulcerative colitis and insights from earlier clinical trials
• Assessing MH002’s mode-of-action and highlighting the CORAL platform’s role in designing potent and scalable LBPs
• Exploring and future applications in pouchitis and immune-oncology through strategic partnerships and pipeline expansion

MRM Health's Representative